Grimes & Company, Inc. Iterum Therapeutics PLC Transaction History

Grimes & Company, Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 22, 2022	BUY	$0.19 - $0.36 $592 - $1,123	3,120 Added 1.77%	179,396 $36,000
Q1 2022 May 06, 2022	BUY	$0.31 - $0.45 $9,125 - $13,247	29,438 Added 20.05%	176,276 $63,000
Q4 2021 Feb 01, 2022	SELL	$0.39 - $0.74 $4,707 - $8,932	-12,071 Reduced 7.6%	146,838 $58,000
Q3 2021 Nov 08, 2021	BUY	$0.54 - $2.29 $6,820 - $28,924	12,631 Added 8.63%	158,909 $89,000
Q2 2021 Aug 04, 2021	BUY	$0.97 - $2.39 $20,991 - $51,721	21,641 Added 17.36%	146,278 $338,000
Q1 2021 May 12, 2021	BUY	$0.97 - $2.73 $51,057 - $143,699	52,637 Added 73.11%	124,637 $176,000
Q4 2020 Feb 02, 2021	BUY	$0.46 - $1.2 $33,120 - $86,400	72,000 New	72,000 $71,000

145

Ticker ITRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 12,233,400
Market Cap $30.1M
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract inf...

Get notified when there are updates to the investment portfolio of Grimes & Company, Inc., based on Form 13F filings with the SEC.

Stay updated on Grimes & Company, Inc. with notifications on news.